Seven clinical conundrums in the treatment of ANCA-associated vasculitis

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.75, 2013, Pages

  Alba, M A ^a   Flores Suarez L F ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

ANCA; Treatment; Vasculitis

Indexed keywords

15 DEOXYSPERGUALIN; ABATACEPT; ARC 905; AZATHIOPRINE; BELIMUMAB; CCX 168; COMPLEMENT; CYCLOPHOSPHAMIDE; ECULIZUMAB; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRAZUMAB; PEXELIZUMAB; PREDNISOLONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

AMENORRHEA; ANCA ASSOCIATED VASCULITIS; ARTICLE; B LYMPHOCYTE; BLADDER CANCER; CLINICAL PROTOCOL; CYSTITIS; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG INDICATION; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFECTION; LEUKOPENIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MYELODYSPLASTIC SYNDROME; PLASMAPHERESIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REMISSION; SIDE EFFECT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; B-LYMPHOCYTES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYCOPHENOLIC ACID; PLASMA EXCHANGE; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878395378     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (170)

1. JENNETTE JC, FALK RJ, BACON PA et al.: 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11.
2. WALTON EW: Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2: 265-70.
3. FLOSSMANN O, BERDEN A, DE GROOT K et al.: Long-term patient survival in ANCAassociated vasculitis. Ann Rheum Dis 2011; 70: 488-94.
4. FAUCI AS, WOLFF SM: Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973; 52: 535-61.
5. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488- 98.
6. MUKHTYAR C, GUILLEVIN L, CID MC et al.: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68: 310-7.
7. GUILLEVIN L, CORDIER JF, LHOTE F et al.: A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-98.
8. DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-9.
9. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
10. JAYNE DR, RASMUSSEN N: Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin Proc 1997; 72: 737-47.
11. KOLDINGSNES W, NOSSENT JC: Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003; 30: 80-8.
12. WEGENER'S GRANULOMATOSIS ETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351- 61.
13. KLEIMAN A, TUCKERMANN JP: Glucocorticoid receptor action in beneficial and side effects of steroid therapy: lessons from conditional knockout mice. Mol Cell Endocrinol 2007; 275: 98-108.
14. STAHN C, BUTTGEREIT F: Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008; 4: 525-33.
15. BUTTGEREIT F, DA SILVA JA, BOERS M et al.: Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis 2002; 61: 718-22.
16. LIPWORTH BJ: Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000; 356: 87-9.
17. RUIZ-IRASTORZA G, DANZA A, KHAMASHTA M: Glucocorticoid use and abuse in SLE. Rheumatology (Oxford) 2012; 51: 1145-53.
18. STAHN C, LOWENBERG M, HOMMES DW, BUTTGEREIT F: Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol 2007; 275: 71-8.
19. BADSHA H, EDWARDS CJ: Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum 2003; 32: 370-7.
20. ILLEI GG, AUSTIN HA, CRANE M et al.: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-57.
21. KONG KO, BADSHA H, LIAN TY, EDWARDS CJ, CHNG HH: Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus 2004; 13: 212-3.
22. WALSH M, MERKEL P, CASIAN A, JAYNE D: PEXIVAS: design of an RCT of PLEX and GC dosing in the treatment of severe ANCA-AAV. Clin Exp Immunol 2011; 164: 67.
23. LANGFORD CA, TALAR-WILLIAMS C, SNELLER MC: Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43: 1836-40.
24. MEIKLE AW, TYLER FH: Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 1977; 63: 200-7.
25. LANGFORD CA, TALAR-WILLIAMS C, BARRON KS, SNELLER MC: Use of a cyclophosphamide- induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114: 463-9.
26. DE GROOT K, REINHOLD-KELLER E, TATSIS E et al.: Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39: 2052-61.
27. HOFFMAN GS, LEAVITT RY, KERR GS, FAUCI AS: The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum 1992; 35: 1322-9.
28. STONE JH: Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003; 48: 2299-309.
29. HOLLE JU, GROSS WL, HOLL-ULRICH K et al.: Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage? Ann Rheum Dis 2010; 69: 1934-9.
30. PAGNOUX C, MAHR A, HAMIDOU MA et al.: Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359: 2790-803.
31. WALSH M, MERKEL PA, MAHR A, JAYNE D: Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 1166-73.
32. MCGREGOR JG, HOGAN SL, HU Y, JENNETTE CE, FALK RJ, NACHMAN PH: Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012; 7: 240-7.
33. NACHMAN PH, HOGAN SL, JENNETTE JC, FALK RJ: Treatment response and relapse in antineutrophil cytoplasmic autoantibody- associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7: 33-9.
34. WALSH M, FLOSSMANN O, BERDEN A et al.: Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 542-8.
35. TALAR-WILLIAMS C, HIJAZI YM, WALTHER MM et al.: Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124: 477-84.
36. SNELLER MC, HOFFMAN GS, TALAR-WILLIAMS C, KERR GS, HALLAHAN CW, FAUCI AS: An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-13.
37. VILLA-FORTE A, CLARK TM, GOMES M et al.: Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 2007; 86: 269-77.
38. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
39. STONE JH, TUN W, HELLMAN DB: Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. J Rheumatol 1999; 26: 1134-9.
40. HELLMICH B, FLOSSMANN O, GROSS WL et al.: EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66: 605-17.
41. STEGEMAN CA, TERVAERT JW, DE JONG PE, KALLENBERG CG: Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335: 16-20.
42. SALLIOT C, VAN DER HEIJDE D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009; 68: 1100-4.
43. GOLDEN MR, KATZ RS, BALK RA, GOLDEN HE: The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22: 1043-7.
44. TZELEPIS GE, KOKOSI M, TZIOUFAS A et al.: Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010; 36: 116-21.
45. ARULKUMARAN N, PERISELNERIS N, GASKIN G et al.: Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011; 50: 2035-43.
46. DE GROOT K, MUHLER M, REINHOLD-KELLER E, PAULSEN J, GROSS WL: Induction of remission in Wegener's granulomatosis with low dose methotrexate. J Rheumatol 1998; 25: 492-5.
47. REINHOLD-KELLER E, FINK CO, HERLYN K, GROSS WL, DE GROOT K: High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47: 326-32.
48. FAURSCHOU M, WESTMAN K, RASMUSSEN N et al.: Long-term outcome of a clinical trial comparing methotrexate to cyclophosphamide for remission induction of early systemic ANCA-associated vasculitis. Arthritis Rheum 2012.
49. FURST DE: Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995; 34 (Suppl. 2): 20-5.
50. NASSONOV EL, SAMSONOV MY, TILZ GP et al.: Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis. J Rheumatol 1997; 24: 666-70.
51. JONASDOTTIR O, PETERSEN J, BENDTZEN K: Tumour necrosis factor-alpha (TNF), lymphotoxin and TNF receptor levels in serum from patients with Wegener's granulomatosis. APMIS 2001; 109: 781-6.
52. NORONHA IL, KRUGER C, ANDRASSY K, RITZ E, WALDHERR R: In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCApositive glomerulonephritis. Kidney Int 1993; 43: 682-92.
53. KINDLER V, SAPPINO AP, GRAU GE, PIGUET PF, VASSALLI P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989; 56: 731-40.
54. FALK RJ, TERRELL RS, CHARLES LA, JENNETTE JC: Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 1990; 87: 4115-9.
55. STONE JH, UHLFELDER ML, HELLMANN DB, CROOK S, BEDOCS NM, HOFFMAN GS: Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. Arthritis Rheum 2001; 44: 1149-54.
56. LANGFORD C, TALAR-WILLIAMS C, BARRON K, MCCABE K, SNELLER M: Phase I/II trial of etanercept in Wegener's granulomatosis (WG): safety and preliminary experience [abstract]. Arthritis and Rheum 2000; 43: S163.
57. SILVA F, SEO P, SCHROEDER DR et al.: Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort. Arthritis Rheum 2011; 63: 2495-503.
58. LAMPRECHT P, VOSWINKEL J, LILIENTHAL T et al.: Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 1303-7.
59. BOOTH A, HARPER L, HAMMAD T et al.: Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-21.
60. BARTOLUCCI P, RAMANOELINA J, COHEN P et al.: Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002; 41: 1126-32.
61. JOSSELIN L, MAHR A, COHEN P et al.: Infliximab efficacy and safety against refractory systemic necrotising vasculitides: longterm follow-up of 15 patients. Ann Rheum Dis 2008; 67: 1343-6.
62. MORGAN MD, DRAYSON MT, SAVAGE CO, HARPER L: Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract 2011; 117: c89-97.
63. DE MENTHON M, COHEN P, PAGNOUX C et al.: Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients. Clin Exp Rheumatol 2011; 29: S63-71.
64. LIN J, ZIRING D, DESAI S et al.: TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 2008; 126: 13-30.
65. WONG M, ZIRING D, KORIN Y et al.: TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126: 121-36.
66. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
67. LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-602.
68. VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774-85.
69. LAURINO S, CHAUDHRY A, BOOTH A, CONTE G, JAYNE D: Prospective study of TNFalpha blockade with adalimumab in ANCA-associated systemic vasculitis withrenal involvement. Nephrol Dial Transplant 2010; 25: 3307-14.
70. COLE E, CATTRAN D, MAGIL A et al.: A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am J Kidney Dis 1992; 20: 261-9.
71. GUILLEVIN L, LHOTE F, COHEN P et al.: Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 1995; 38: 1638-45.
72. PUSEY CD, REES AJ, EVANS DJ, PETERS DK, LOCKWOOD CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int 1991; 40: 757-63.
73. WALSH M, CATAPANO F, SZPIRT W et al.: Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011; 57: 566-74.
74. ZAUNER I, BACH D, BRAUN N et al.: Predictive value of initial histology and effect of plasmapheresis on long-term prognosis of rapidly progressive glomerulonephritis. Am J Kidney Dis 2002; 39: 28-35.
75. JAYNE DR, GASKIN G, RASMUSSEN N et al.: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-8.
76. GLASSOCK RJ: Intensive plasma exchange in crescentic glomerulonephritis: help or no help? Am J Kidney Dis 1992; 20: 270-5.
77. ANDERSON G, COLES ET, CRANE M et al.: Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992; 83: 427-38.
78. CORDIER JF, VALEYRE D, GUILLEVIN L, LOIRE R, BRECHOT JM: Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest 1990; 97: 906-12.
79. GUILLEVIN L, DURAND-GASSELIN B, CEVALLOS R et al.: Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-30.
80. BOSCH X, FONT J, MIRAPEIX E, REVERT L, INGELMO M, URBANO-MARQUEZ A: Antimyeloperoxidase autoantibody-associated necrotizing alveolar capillaritis. Am Rev Respir Dis 1992; 146: 1326-9.
81. MACKAY J: Rapidly progressive pulmonary haemorrhage in a case of microscopic polyangiitis. BMJ Case Rep 2011; 2011.
82. WANG CC, SHIANG JC, TSAI MK et al.: Prompt plasmapheresis successfully rescue pulmonary-renal syndrome caused by ANCA-negative microscopic polyangiitis. Clin Rheumatol 2009; 28: 1457-60.
83. AZUMA M, SASAKI S, MOCHIDUKI Y et al.: [A case of ANCA-associated vasculitis with diffuse alveolar hemorrhage successfully treated by plasmapheresis]. Nihon Kokyuki Gakkai Zasshi 2007; 45: 21-5.
84. SUGIMOTO T, DEJI N, KUME S et al.: Pulmonary-renal syndrome, diffuse pulmonary hemorrhage and glomerulonephritis, associated with Wegener's granulomatosis effectively treated with early plasma exchange therapy. Intern Med 2007; 46: 49-53.
85. NGUYEN T, MARTIN MK, INDRIKOVS AJ: Plasmapheresis for diffuse alveolar hemorrhage in a patient with Wegener's granulomatosis: case report and review of the literature. J Clin Apher 2005; 20: 230-4.
86. PONS-ESTEL GJ, SALERNI GE, SERRANO RM et al.: Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Autoimmun Rev 2011; 10: 679-84.
87. SASAKI S, MOCHIZUKI Y, NAKAHARA Y et al.: [Seven cases of diffuse alveolar hemorrhage with acute respiratory failure treated by plasma exchange]. Nihon Kokyuki Gakkai Zasshi 2010; 48: 10-6.
88. GALLAGHER H, KWAN JT, JAYNE DR: Pulmonary renal syndrome: a 4-year, singlecenter experience. Am J Kidney Dis 2002; 39: 42-7.
89. KLEMMER PJ, CHALERMSKULRAT W, REIF MS, HOGAN SL, HENKE DC, FALK RJ: Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis 2003; 42: 1149-53.
90. FAUCI AS, HAYNES BF, KATZ P, WOLFF SM: Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
91. DE GROOT K, ADU D, SAVAGE CO: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001; 16: 2018-27.
92. DE GROOT K, HARPER L, JAYNE D et al.: Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-80.
93. JONES RB, TERVAERT JW, HAUSER T et al.: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-20.
94. STONE JH, MERKEL PA, SPIERA R et al.: Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-32.
95. ALBA MA, FLORES-SUAREZ LF: [Rituximab for the treatment of ANCA associated vasculitis: the future today?]. Reumatol Clin 2011; 7 Suppl 3: S41-6.
96. HOGAN SL, FALK RJ, CHIN H et al.: Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143: 621-31.
97. MUKHTYAR C, FLOSSMANN O, HELLMICH B et al.: Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67: 1004-10.
98. GAYRAUD M, GUILLEVIN L, COHEN P et al.: Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36: 1290-7.
99. GAYRAUD M, GUILLEVIN L, LE TOUMELIN P et al.: Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-75.
100. SEROR R, PAGNOUX C, RUIVARD M et al.: Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. Ann Rheum Dis 2010; 69: 2125-30.
101. HARPER L, MORGAN MD, WALSH M et al.: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71: 955-60.
102. SPECKS U, STONE JH: Long-term effi cacy and safety results of the RAVE trial. Clin EXp Immunol 2011; 164: 65.
103. HOLLE JU, GROSS WL, LATZA U et al.: Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades. Arthritis Rheum 2011; 63: 257-66.
104. PAGNOUX C, HOGAN SL, CHIN H et al.: Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008; 58: 2908-18.
105. PIERROT-DESEILLIGNY DESPUJOL C, POUCHOT J, PAGNOUX C, COSTE J, GUILLEVIN L: Predictors at diagnosis of a first Wegener's granulomatosis relapse after obtaining complete remission. Rheumatology (Oxford) 2010; 49: 2181-90.
106. LANGFORD CA: Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis. Clin Exp Immunol 2011; 164 (Suppl. 1): 31-4.
107. LANGFORD CA, TALAR-WILLIAMS C, BARRON KS, SNELLER MC: A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42: 2666-73.
108. ALLISON AC: Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14 (Suppl. 1): s2-8.
109. SOLLINGER HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-32.
110. LANG P, PARDON A, AUDARD V: Long-term benefit of mycophenolate mofetil in renal transplantation. Transplantation 2005; 79: S47-8.
111. APPEL GB, CONTRERAS G, DOOLEY MA et al.: Mycophenolate mofetil versus cyclophosphamide for induction treatment oflupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
112. GINZLER EM, DOOLEY MA, ARANOW C et al.: Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28.
113. KAMANAMOOL N, MCEVOY M, ATTIA J, INGSATHIT A, NGAMJANYAPORN P, THAKKINSTIAN A: Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore) 2010; 89: 227-35.
114. STASSEN PM, TERVAERT JW, STEGEMAN CA: Induction of remission in active antineutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66: 798-802.
115. HU W, LIU C, XIE H, CHEN H, LIU Z, LI L: Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant 2008; 23: 1307-12.
116. JOY MS, HOGAN SL, JENNETTE JC, FALK RJ, NACHMAN PH: A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol Dial Transplant 2005; 20: 2725-32.
117. KOUKOULAKI M, JAYNE DR: Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract 2006; 102: c100-7.
118. PESAVENTO T, FALKENHAIN M, ROVIN B, HEBERT L: Mycophenolate mofetil therapy (MMF) in anti-neutrophil cytoplasmic antibody (ANCA) vascultis [abstract]. J Am Soc Nephrol 1999; 10: 114A.
119. HAIDINGER M, NEUMANN I, GRUTZMACHER H, BAYER P, MEISL F: Mycophenolate mofetil (MMF) treatment of ANCA-assocaited small-vessel vasculitis: a pharmacokinetically controlled study. [abstract]. Clin Exp Immunol 2000; 120 (Suppl. 1): 72.
120. IATROU C, ZERBALA S, REVELA I et al.: Mycophenolate mofetil as maintenance therapy in patients with vasculitis and renal involvement. Clin Nephrol 2009; 72: 31-7.
121. HIEMSTRA TF, WALSH M, MAHR A et al.: Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304: 2381-8.
122. JONES R, WALSH M: A Randomised Trial of Mycophenolate Mofetil versus Cyclophosphamide for Remission Induction in ANCAAssociated Vasculitis: MYCYC [Abstract]. J Am Soc Nephrol 2012; 23.
123. LANGFORD CA, TALAR-WILLIAMS C, SNELLER MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51: 278-83.
124. NOWACK R, GOBEL U, KLOOKER P, HERGESELL O, ANDRASSY K, VAN DER WOUDE FJ: Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999; 10: 1965-71.
125. TALARICO R, BALDINI C, DELLA ROSSA A et al.: Large-and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clin Exp Rheumatol 2012; 30: S130-8.
126. ARIES PM, HELLMICH B, VOSWINKEL J et al.: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-8.
127. BRIHAYE B, AOUBA A, PAGNOUX C, VIGNAUX O, LE HELLO C, GUILLEVIN L: Rituximab reversed cardiac involvement of Wegener's granulomatosis: magnetic resonance imaging assessment. Presse Med 2008; 37: 412-5.
128. ERIKSSON P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J Intern Med 2005; 257: 540-8.
129. HENES JC, FRITZ J, KOCH S et al.: Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. Clin Rheumatol 2007; 26: 1711-5.
130. JONES RB, FERRARO AJ, CHAUDHRY AN et al.: A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-68.
131. KEOGH KA, WYLAM ME, STONE JH, SPECKS U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-8.
132. KEOGH KA, YTTERBERG SR, FERVENZA FC, CARLSON KA, SCHROEDER DR, SPECKS U: Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-7.
133. LOVRIC S, ERDBRUEGGER U, KUMPERS P et al.: Rituximab as rescue therapy in antineutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. Nephrol Dial Transplant 2009; 24: 179-85.
134. MANSFIELD N, HAMOUR S, MARIE-HABIB A et al.: Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis. Nephrol Dial Transplant 2011.
135. OMDAL R, WILDHAGEN K, HANSEN T, GUNNARSSON R, KRISTOFFERSEN G: Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005; 34: 229-32.
136. ROCCATELLO D, BALDOVINO S, ROSSI D et al.: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004; 19: 3054-61.
137. SANCHEZ-CANO D, CALLEJAS-RUBIO JL, ORTEGO-CENTENO N: Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol 2008; 14: 92-3.
138. SEO P, SPECKS U, KEOGH KA: Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35: 2017-23.
139. SMITH KG, JONES RB, BURNS SM, JAYNE DR: Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-82.
140. STASI R, STIPA E, DEL POETA G, AMADORI S, NEWLAND AC, PROVAN D: Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006; 45: 1432-6.
141. TAMURA N, MATSUDAIRA R, HIRASHIMA M et al.: Two cases of refractory Wegener's granulomatosis successfully treated with rituximab. Intern Med 2007; 46: 409-14.
142. FORTIN PM, TEJANI AM, BASSETT K, MUSINI VM: Intravenous immunoglobulin as adjuvant therapy for Wegener's granulomatosis. Cochrane Database Syst Rev 2009; CD007057.
143. JAYNE DR, CHAPEL H, ADU D et al.: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000; 93: 433-9. 144. JAYNE DR, LOCKWOOD CM: Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35: 1150-3.
144. JAYNE DR, LOCKWOOD CM: Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol 1996; 35: 1150-3.
145. MARTINEZ V, COHEN P, PAGNOUX C et al.: Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, openlabel study of twenty-two patients. Arthritis Rheum 2008; 58: 308-17.
146. RICHTER C, SCHNABEL A, CSERNOK E, DE GROOT K, REINHOLD-KELLER E, GROSS WL: Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995; 101: 2-7.
147. MUZAFFAR J, KATRAGADDA L, HAIDER S, JAVED A, ANAISSIE E, USMANI S: Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature. Int J Hematol 2012; 95: 102-6.
148. VO AA, LUKOVSKY M, TOYODA M et al.: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-51.
149. HONG YA, KIM HG, CHOI SR et al.: Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection. Transplant Proc 2012; 44: 182-4.
150. FELDMAN RJ, CHRISTEN WG, AHMED AR: Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy. Br J Dermatol 2012; 166: 511-7.
151. AHMED AR, SPIGELMAN Z, CAVACINI LA, POSNER MR: Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-9.
152. BAYRY J, NEGI VS, KAVERI SV: Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011; 7: 349-59.
153. KESSEL A, ROSNER I, TOUBI E: Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol 2008; 34: 74-9.
154. KESSEL A, AMMURI H, PERI R et al.: Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007; 179: 5571-5.
155. SAMUELSSON A, TOWERS TL, RAVETCH JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-6.
156. TEELING JL, JANSEN-HENDRIKS T, KUIJPERS TW et al.: Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001; 98: 1095-9.
157. JAYNE DR, DAVIES MJ, FOX CJ, BLACK CM, LOCKWOOD CM: Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991; 337: 1137-9.
158. DIETRICH G, KAVERI SV, KAZATCHKINE MD: Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 1992; 62: S73-81.
159. KAVERI SV, DIETRICH G, HUREZ V, KAZATCHKINE MD: Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1991; 86: 192-8.
160. CHEN M, DAHA MR, KALLENBERG CG: The complement system in systemic autoimmune disease. J Autoimmun 2010; 34: J276-86.
161. FLORES-SUAREZ LF: [The complement system in the pathogenesis of antineutrophil cytoplasm antibodies-associated vasculitis]. Reumatol Clin 2011; 7 Suppl 3: S18-21.
162. VAN TIMMEREN MM, CHEN M, HEERINGA P: Review article: Pathogenic role of complement activation in anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Nephrology (Carlton) 2009; 14: 16-25.
163. XIAO H, HEERINGA P, HU P et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-63.
164. SCHREIBER A, XIAO H, JENNETTE JC, SCHNEIDER W, LUFT FC, KETTRITZ R: C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009; 20: 289-98.
165. HUUGEN D, VAN ESCH A, XIAO H et al.: Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007; 71: 646-54.
166. XIAO H, SCHREIBER A, HEERINGA P, FALK RJ, JENNETTE JC: Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007; 170: 52-64.
167. CHEN M, XING GQ, YU F, LIU G, ZHAO MH: Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant 2009; 24: 1247-52.
168. XING GQ, CHEN M, LIU G et al.: Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009; 29: 282-91.
169. YUAN J, GOU SJ, HUANG J, HAO J, CHEN M, ZHAO MH: C5a and its receptors in human anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Arthritis Res Ther 2012; 14: R140.
170. WOODRUFF TM, NANDAKUMAR KS, TEDESCO F: Inhibiting the C5-C5a receptor axis. Mol Immunol 2011; 48: 1631-42.